Interesting days at the Euroanesthesia 2017 meeting

Uppsala, June 8, 2017. As previously announced, Senzime AB (publ) participated at the Euroanesthesia (ESA) 2017 meeting in Geneva Switzerland June 3-5. ESA is the leading European Organisation for Anaesthesia, Critical Care, Pain and Perioperative Medicine. 

With over 6000 international delegates and 100 exhibitors from more than 80 countries, Euroanesthesia is a great international platform in anesthesia to enhance knowledge; review innovative techniques and network with representatives of a large international audience.

Senzime participated with a booth and met with a great amount of the clinicians visiting the meeting. We now have several potential customer and distributors to follow up with during the upcoming weeks.

Present at the meeting was also Dr Réka Nemes from the University of Debrecen, Department of Anesthesiology and Intensive Care, Debrecen, Hungary.  

“As a clinician, I am happy to educate peer fellows on the benefits of using objective monitoring. I have used the TetraGraph during clinical studies and find it very effective and easy to use”, says Réka Nemes, Dr at the University of Debrecen.

For further information, please contact: 

Lena Söderström, CEO

Tel: +46-70-816 39 12 email:


About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. 

Om oss

Senzime utvecklar unika medicintekniska lösningar som gör det möjligt att följa patienters biokemiska och fysiologiska processer inför, under och efter operation. I portföljen ingår patientnära system som möjliggör automatiserad och kontinuerlig mätning av livskritiska ämnen som glukos och laktat i blod och vävnader samt system för att monitorera patienter som undergår narkos. Lösningarna syftar till att säkerställa maximal patientnytta, minska komplikationer i samband med operationer och minska vårdkostnader. Senzime verkar på växande marknader som idag enbart i Europa och USA värderas till över 10 miljarder SEK. Bolagets aktie är noterad på Nasdaq First North (ticker SEZI). FNCA är Certified Adviser för Senzime.


Dokument & länkar